Work

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

Year: 2019

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz338.077

Authors: Pasi A. Jänne, Joel W. Neal, D.R. Camidge, Alexander Spira, Zofia Piotrowska, Leora Horn, Daniel B. Costa, Anne Tsao, Jyoti Patel, Shirish Gadgeel, Lyudmila Bazhenova, Viola W Zhu, Howard West, Sylvie Vincent, Jian Zhu, Shuanglian Li, Gregory J. Riely

Institutions: Dana-Farber Cancer Institute, Stanford Cancer Institute, Stanford University, University of Colorado Cancer Center, Virginia Cancer Specialists, Massachusetts General Hospital, Vanderbilt-Ingram Cancer Center, Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, University of Chicago, University of Michigan, University of California San Diego, Moores Cancer Center, University of California, Irvine, Takeda Oncology (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2979730200

FWCI: 0.826

Cites:

Cited by: 8

Related to: 10